Short Interest in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Rises By 20.5%

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) saw a large increase in short interest in the month of December. As of December 31st, there was short interest totaling 3,166,818 shares, an increase of 20.5% from the December 15th total of 2,628,101 shares. Based on an average daily volume of 2,555,483 shares, the days-to-cover ratio is presently 1.2 days. Currently, 17.1% of the shares of the company are sold short. Currently, 17.1% of the shares of the company are sold short. Based on an average daily volume of 2,555,483 shares, the days-to-cover ratio is presently 1.2 days.

Citius Pharmaceuticals Price Performance

Shares of NASDAQ:CTXR traded down $0.04 during midday trading on Tuesday, reaching $0.82. The company’s stock had a trading volume of 273,532 shares, compared to its average volume of 291,516. The business’s fifty day simple moving average is $1.03 and its 200-day simple moving average is $1.27. Citius Pharmaceuticals has a fifty-two week low of $0.63 and a fifty-two week high of $3.40. The company has a market capitalization of $17.00 million, a P/E ratio of -0.24 and a beta of 1.56.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. D. Boral Capital reiterated a “buy” rating and issued a $6.00 target price on shares of Citius Pharmaceuticals in a research note on Thursday, December 4th. Wall Street Zen upgraded Citius Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Saturday, December 27th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Citius Pharmaceuticals presently has an average rating of “Hold” and an average price target of $6.00.

Institutional Investors Weigh In On Citius Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Arkadios Wealth Advisors boosted its stake in Citius Pharmaceuticals by 100.0% in the second quarter. Arkadios Wealth Advisors now owns 20,000 shares of the company’s stock valued at $32,000 after acquiring an additional 10,000 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Citius Pharmaceuticals in the 2nd quarter worth $32,000. Finally, NewEdge Advisors LLC bought a new position in shares of Citius Pharmaceuticals in the 2nd quarter worth $40,000. 16.88% of the stock is owned by institutional investors.

About Citius Pharmaceuticals

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.